All business segments, particularly Healthcare-Big Data, expanded steadily. The organic growth of our core business is driving the overall growth.
Consolidated revenue
(Million JPY)
15,679
Y-o-Y
+35％
Consolidated EBITDA
(Million JPY)
4,580
Y-o-Y
+39％
Healthcare-
Big Data
Y-o-Y
+46％
Tele-medicine and
Dispensing
Pharmacy Support
Y-o-Y
Tele-medicine
Dispensing
Pharmacy Support
+12％ +32％
JMDC
(non-consolidated)
net sales growth
Y-o-Y
+39％
JMDC
(non-consolidated)
EBITDA growth
Y-o-Y
+63％
3
Note: IFRS-based
EBITDA: Operating profit + Depreciation and amortization costs ± Other profits and/or losses
FY2021 Q3: Summary of Consolidated Performance
We maintain a high level of profitability by expanding our workforce in balance with our business growth.
(Unit: Million JPY)
FY2020 Q3
FY2021 Q3
Y-o-Y
Revenue
Operating profit
(Rate)
Profit before taxes
(Rate)
Profit attributable to
owners of parent
(Rate)
EBITDA (Margin)
11,606
15,679
2,424
3,417
(21%)
(22%)
2,406
3,408
(21%)
(22%)
1,578
2,280
(14%)
(15%)
3,284
4,580
(28%)
(29%)
+35%
+41%
+42%
+44%
+39%
4
Note: IFRS-based
EBITDA: Operating profit + Depreciation and amortization costs ± Other profits and/or losses, EBITDA margin: EBITDA/Revenue
FY2021 Q3: Consolidated Revenue/EBITDA
The trend of the previous fiscal quarter, when performance expanded rapidly, has been firmly sustained.
Quarterly trends of consolidated revenue
Quarterly trends of consolidated EBITDA/margin
(Unit: Million JPY)
(Unit: Million JPY and %)
+ 32%
6,128
4,630
5,165
4,530
5,020
3,503
3,212
3,763
3,068
3,028
2,558
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
FY2019
FY2020
FY2021
35
34
EBITDA
31
margin
+ 30%
2,107
EBITDA
1,619
1,582
1,164
1,308
934
993
1,050
835
614
480
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
FY2019
FY2020
FY2021
5
Note: IFRS-based
EBITDA: Operating profit + Depreciation and amortization costs ± Other profits and/or losses, EBITDA margin: EBITDA/Revenue
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
JMDC Inc. published this content on 07 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 February 2022 06:07:03 UTC.
JMDC Inc. is a Japan-based company mainly engaged in the health big data business, telemedicine business and dispensing pharmacy support business. The Company operates in three business segments. The Health Big Data segment is engaged in the provision of receipt data analysis and health promotion solutions, and personal health information platforms, the build, management and analysis of medical databases such as receipt data and medical examination data, the build and sale of drug databases, and the development and provision of systems using drug databases for medical institutions. The Telemedicine segment is engaged in the provision of remote image diagnosis matching services, and infrastructure systems for remote image diagnosis. The Dispensing Pharmacy Support segment is engaged in the development and provision of business systems and electronic medication record for dispensing pharmacies, as well as the operation of dispensing pharmacies.
JMDC INC. 
